A Key Therapeutic System for Reversing MAFLD-related Cirrhosis: a Randomized Double-blind Controlled Trial on the Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Chiglitazar (Primary)
- Indications Fatty liver; Liver cirrhosis
- Focus Therapeutic Use
- 21 Jan 2025 New trial record